Drug Information Association Logo
Corporate Tagline

CardioVascular Safety: The New Paradigm - Proarrhythmic Assessment of New Drugs without the Thorough QT Study

| Online

« Back to Listing

Overview 

Continuing Education credit or Certificate Program units are not available for Archived Webinars


This webinar will explore the current approach to assessing the possible proarrhyrhmic potential of drugs and its strengths and weaknesses, a new paradigm that relies more fully on preclinical testing and its advantages and challenges, and key regulatory issues surrounding implementing a new paradigm.


Access to the presentations are not available for this Archived Webinar.  With purchase you will receive the archived webinar recording, and be able to view the slide deck, however you will not be able to download the power point presentations.





This webinar was developed in collaboration with the Cardiac Safety Research Consortium (CSRC)

Who Should Attend 

Physicians, Pharmacists, Nurses, Regulatory Experts and others involved in:

  • Development of pharmaceutical products
  • Safety / Pharmacovigilance
  • Drug Development
  • Risk Management
  • Nonclinical

Learning Objectives 

At the conclusion of this webinar, participants should be able to:

  • Explain the benefits and challenges of the current approach to assessing the possible proarrhyrhmic potential of drugs
  • Discuss the key aspects of the new paradigm and be updated on its progress
  • Describe the regulatory context

Contact Information 

Questions on Archived Webinar
Jessica Culp
DIA North America
Phone +1.215.442.6132
Fax +1.215.442.6199
Jessica.Culp@diahome.org

Technical Requirements 

Click here for minimum system requirements.

Presenter(s) 

Previous Next

Agenda  

Day 1 Wednesday, Nov 06, 2013

  • 7:00AM - 11:59PM

    CardioVascular Safety: The New Paradigm - Proarrhythmic Assessment of New Drugs without the Thorough QT Study


    Session Chair(s):

    • Philip T. Sager, MD, FACC
      Consulting Professor of Medicine-Stanford; Chair, Scientific Programs Committee
      Stanford University, United States

    Speaker(s):

    • Norman Stockbridge, MD, PhD
      Director, Division of Cardiovascular and Renal Products, OND, CDER
      FDA, United States
    • Gary Gintant, PhD, MA
      Research Fellow
      AbbVie Inc., United States

Registration Fees 

Other Fees

Group Site
$799.00
Group Plus
$995.00

Member

Member Government Individual
$125.00
Member Academia Individual
$175.00
Member Individual
$250.00

Non-Member

NonMember Government Individual
$125.00
NonMember Academia Individual
$175.00
NonMember Individual
$295.00
Group Discounts

  • Group site registration is a license for ONE internet login allowing multiple viewers from one location.
  • Group Plus is a license for up to FIVE internet logins allowing one or more viewers at each login location.


CANCELLATIONS
No refunds will be provided in the event of a participant’s cancellation since all costs for this webinar have been prepaid by DIA. DIA reserves the right to modify or cancel programs and/or substitute presenters or panelists. DIA is not responsible for failure to deliver programs due to circumstances beyond its control.

Participants with Disabilities: Reasonable accommodations will be made available to persons with disabilities who attend an educational activity. Contact the DIA office in writing at least 15 days prior to event to indicate your needs.

Register Online

Unless otherwise disclosed, the statements made by speakers represent their own opinions and not necessarily those of the organization they represent, or that of the Drug Information Association. Speakers, agenda and CE information are subject to change without notice. Recording of any DIA educational material in any type of media is prohibited without prior written consent from DIA.

« Back to Listing Back To Top